Kimberly Finn & Gaurang Majmudar are attending Fierce Biotech Week 7-9 Oct 2025- Bos
Our Core Team of Experts
Our Leadership Team
Our leadership team, led by Founder & CEO Kimberly Finn and Co-Founder & CSO Gaurang Majmudar, brings together decades of expertise in drug development innovation, operations, and strategic development. Supported by Amy Gutierrez and Amy Pinette together with a network of strategic consultants, Bioclinical Solutions is committed to driving innovation and delivering impactful healthcare solutions.
Kimberly Finn, Founder and CEO
Kimberly Finn is a pharmaceutical executive and clinical operations strategist with over 30 years of experience driving global R&D programs across biotech, pharma and CROs. As Founder and CEO of BioClinical Solutions, she brings deep expertise in building scalable departments, cross-functional service lines, and sponsor-facing clinical trial frameworks that support both traditional and decentralized clinical trials.
Her leadership has successfully designed and launched global service delivery models, including the development of global project management departments and specialized offerings such as Home Health Care and direct-to-patient/direct-from-patient (DTP/DFP) services. She has consistently optimized vendor oversight and driven successful NDA submissions across a broad range of therapeutic areas.
Kimberly has successfully led the development and execution of study drug programs ranging from large-scale, multi-country mega trials to rare and orphan indications—delivering operational excellence, regulatory alignment, and accelerated timelines.
Based in Chicago, IL, Kimberly continues to champion ethical, transparent, and patient-centered innovation in clinical research, guiding sponsors and partners toward leaner, smarter trial execution.
Gaurang Majmudar, Founding Partner and CSO
Gaurang Majmudar, is a pharmaceutical professional with a 30+ years track record of delivering excellence, both strategically and commercially. Executive experience across the pharmaceutical development lifecycle, in roles that uniquely span from Clinical Operations to Commercialization. Gaurang has passionately focused on patient centricity and has successfully built HHC operations in Europe and APAC resulting in the launch of numerous first in country patient centric Decentralized Clinical Studies & Patient Access solutions for Specialty, and Rare Disease medicines. Gaurang is based in the London, UK
Amy Gutierrez, Sr. Director, Operations
Amy Gutierrez is a Clinical Research professional with 25+ years of expertise in the CRO, Pharmaceutical, and Biotech environments with extensive experience within Project Management and Study Start-Up. Expertise extends to site start-up, including knowledge of site staff experience/requirements for study selection, regulatory requirements to begin a trial, completion of documentation for start-up, as well working with vendors to ensure that site is ready for site activation. Amy's Project Management, focus on site ID, working with sites to ensure rapid start-up for study start and during the clinical trial maintaining enrollment goals, working with vendors for start-up and throughout the clinical trial to ensure milestones are met and the study begins and ends per sponsor timelines, and general study maintenance including budget management during the life cycle of the study.
Amy is based in Wilmington, NC
Amy (Skydel) Pinette, Senior Consultant
Amy (Skydel) Pinette is a distinguished leader in the biotechnology and pharmaceutical industry, boasting over three decades of experience in clinical operations, program management, and cross-functional team leadership strategy and operations. Her career is marked by high-level executive roles within Biotech and CROs space with significant contributions to the advancement of neuroscience and gene therapy research and clinical trials.
Her experience includes multiple neuroscience indications including MS, ALS, Parkinson’s Disease, Alzheimer’s Disease, epilepsy, migraine, Duchenne Muscular Dystrophy, schizophrenia, bipolar disorder, and others. She has worked across different mechanisms of action and methods of administration from Phase I through large, global, Phase III trials. Her most recent gene therapy experience is working on such trials in ALS, Fabry Disease, and epilepsy beginning with IND preparation and submission through study start up for PhaseI/II trials in these indications. Amy began her career as a CRA at BMS and held positions of increasing responsiblity at UniQure, Parexel, InVentiv, and Premier Research (formerly SCIREX).
Amy holds a Bachelor of Science in Biology from McGill University and a master's degree in Neuroscience from the University of Hartford.
Amy’s strategic vision, dedication, and extensive expertise make her a driving force in the biotechnology and pharmaceutical industry, committed to bridging the gap between scientific discovery and patient care. Amy is based in Connecticut.
Michael O'Kane, Strategic Growth Consultant
Michael O'Kane has over 15 years of global experience supporting clinical trials, he brings a proven ability to develop high-impact partnerships, open new markets, and accelerate growth for life sciences organizations.
Throughout his career, Michael has supported clinical development programs across biotech, ATMP/cell & gene therapy firms, and CDMOs, working with stakeholders from R&D teams and early-stage innovators to mid-sized and global biopharma. His deep understanding of clinical operations, combined with a strong commercial mindset, enables him to design and execute strategic go-to-market initiatives that deliver measurable results.
Michael has held senior commercial roles at companies in the sector, while also advising start-ups and CRO teams on growth strategies, client acquisition, and partnership development.
We’re excited to collaborate with Michael as we continue to support biotech clients with tailored CRO and consulting services across every phase of the clinical journey. Michael is based in Dublin, Ireland.